1-3 of 3
Rafael Madero-Marroquin
Close
Sort by
Journal Articles

Analysis of CD58 As a Predictive Marker of Morphologic Response to Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia

Rafael Madero-Marroquin, Ryan Hunter, Caner Saygin, Hannah Johnston, Hamed Rahmani Youshanlouei, Clinton Osei, Wendy Stock, Sandeep Gurbuxani, Anand Ashwin Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 6071.
https://doi.org/10.1182/blood-2023-180883
Published: 2023
Journal Articles

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Douglas Tremblay, MD, Rafael Madero-Marroquin, MD, Guido Lancman, MD, Alexander Coltoff, MD, Jonathan Feld, MD, Jessica Caro, MD, Nicole Zubizarreta, MPH, Marina Kremyanskaya, Alla Keyzner, MD, Michal Bar-Natan, MD, Shyamala C. Navada, MD, Lewis R. Silverman, Janice L. Gabrilove, MD, John Mascarenhas, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5102.
https://doi.org/10.1182/blood-2019-123288
Published: 2019
Journal Articles

Aberrant Hedgehog Signaling in Myelodysplastic Syndrome Accelerates Leukemic Transformation Via Smoothened-Dependent and Smoothened-Independent Gli1 Activation

Bonnie W Lau, MD PhD, Kyounghee Huh, MS, Rafael Madero-Marroquin, MD, Federico De Marchi, MD, Yiting Lim, PhD, Francisco Lobo, PhD, Luigi Marchionni, PhD, Peter D. Aplan, MD, William Matsui, MD, Lukasz P. Gondek, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1676.
https://doi.org/10.1182/blood.V130.Suppl_1.1676.1676
Published: 2017